Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131I-rituximab in Relapsed/Refractory Marginal Zone B-cell Lymphoma
NCT01678404Phase 2Unknown
- Sponsor
- Korea Cancer Center Hospital
- Start
- Oct 2011
- Primary completion
- Sep 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of iodine-131-rituximab in marginal zone B-cell lymphoma (MZL), sponsored by Korea Cancer Center Hospital. Status: unknown.
02
Drugs
iodine-131-rituximab
03
Conditions
marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on NCT01678404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01678404.